Compare Southern Copper Corp (SCCO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southern Copper Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Southern Copper Corp trades at $203.88 (market cap $167.74B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Southern Copper Corp is the larger of the two by market cap, and Southern Copper Corp pays a 2.21% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SCCO | VRTX | |
|---|---|---|
Market Cap | $167.74B | $127.55B |
Volume | 853,110 | 1,487,944 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $557.96 |
52-Week Low | $120.02 | $407.37 |
Typical Hold Time | 61 Days | 120 Days |
Enterprise Value | $169.03B | $121.68B |
Dividend Yield | 2.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCCO trades at $200.57, down 1.81% on the day, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and impressive profitability margins including 35.87% net income margin. Recent earnings beats and a $10.2B Mexican project pipeline support growth prospects, though the stock trades at premium valuations with P/E of 30.1 and P/S of 10.82.
While SCCO's operational strength and copper demand from AI infrastructure provide upside potential, the stock faces headwinds from its premium valuation relative to peers and mixed analyst sentiment with only 10.34% buy ratings. The current price sits above the consensus target of $167.67, suggesting limited near-term upside despite strong cash flow generation and dividend payments.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
